7results about How to "Good antitumor effect" patented technology

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating recurrent or refractory non-Hodgkin lymphoma after receiving at least one standard treatment regimen, and the drug combination comprises the anti-CD20 antibody drug conjugate and at least one therapeutic agent, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The invention discloses an application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating non-Hodgkin lymphoma, and the drug combination comprises the anti-CD20 antibody drug conjugate and bendamustine, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

This invention belongs to the field of biomedical technology, specifically relating to triptolide liposomes (TP-lipo), their combined use, and their application in the prevention and treatment of tumors. To enhance the efficacy of triptolide in the treatment and prevention of tumors such as pancreatic cancer, cervical cancer, ovarian cancer, and colorectal cancer, and to improve its bioavailability and clinical application while reducing toxicity, this invention uses HSPC, DOPS, and cholesterol as liposome components to encapsulate triptolide monomers, thus preparing TP-lipo. Experiments have shown that TP-lipo exhibits anti-tumor activity: it directly kills tumor cells and reverses the immunosuppressive microenvironment, making it a potential drug for tumor treatment. TP-lipo, when used in combination with PD-1 antibodies, or in combination with radiotherapy, chemotherapy, or surgery, demonstrates a potent and synergistic anti-tumor effect with low toxicity. Therefore, the TP-lipo of this invention provides more clinical strategies for tumor treatment.

According to the method for efficiently preparing the natural killer cells, through combined application of optimized three-dimensional scaffold culture and tumor antigens, the amplification efficiency and killing activity of the NK cells are remarkably improved. The method is applied to treatment of diseases such as tumors and virus infection, and has remarkable clinical application value.

The present invention relates to the field of biomedicine technology, and in particular to a deuterated molecular glue that can selectively induce the formation of a type 3A phosphodiesterase (PDE3A) and SLFN12 complex and apoptosis of tumor cells, a preparation method thereof, and an application thereof in tumor treatment.

The present invention belongs to the field of biomedicine technology, and specifically relates to the use of OX40 activating antibodies and anti-angiogenic agents in the preparation of anti-tumor drugs. The OX40 activating antibody is OX86, and the anti-angiogenic agent is verteporfin. OX40 causes an "anti-tumor" effect in T cells and induces a "pro-tumor" effect in endothelial cells. Therefore, the OX40 activating antibody and the anti-angiogenic agent are used in combination, and while activating the OX40 "anti-tumor" signal in T cells, the anti-angiogenic agent is used to block the "pro-tumor" effect of the OX40 activating antibody in endothelial cells. The two components act synergistically, showing a better tumor inhibition effect than the combined treatment of OX40 activating antibody and PD-1 monoclonal antibody (CD279).